End to plan for merger with Presidio follows BioCryst R&D setbacks
This article was originally published in Scrip
BioCryst Pharmaceuticals and Presidio Pharmaceuticals announced merger plans on 18 October to create a company focused on orphan and infectious diseases, with a strong focus on hepatitis C virus (HCV). But before the month was through, the first of at least three negative events for BioCryst had put the pact in jeopardy, and by 30 November the companies terminated their proposed transaction.
You may also be interested in...
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.